AzTrials
AzTrials

MigraineSalHeadNCT03727672

Salivary Inflammatory Markers in Tension Type Headache and Migraine

An observational study of Migraine and Tension-Type Headache, run by National and Kapodistrian University of Athens at 1 site in Greece.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age… Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Migraine, Tension-Type Headache
How many people
90 participants
Where
1 siteGreece
Study dates
1 Jan 2016to 30 Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. Fifteen healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives

Who may be able to join

  • aged from 18 to 60 years old
  • Tension type Headache (TTH) and migraine, fulfilling the criteria International Classification of Headache Disorders, 3rd edition (beta version)

Who cannot join

  • abnormal plasma CRP, Interleukin-1β and Interleukin-6 levels (>10 mg/L)
  • smoking cigarettes > 1 pack/day;
  • current pregnancy, lactation, or hormonal contraceptive use
  • alcohol or substance abuse
  • drug use such as anticoagulants, statins, or hormonal drugs
  • anti-inflammatory therapy
Show all 9Show fewer
  • other primary or secondary headaches
  • major psychiatric disease
  • oral health problems.

Trial locations and contacts

1 site in 1 country.

Greece1 site
  • Eginition Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Athens, 11528

Other trials in Greece

About this study

Official title: Salivary Inflammatory Markers (Interleukin -1β, Interleukin -6, C- Reactive Protein) in Tension Type Headache and Migraine

Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age matched healthy controls . Τhe investigators, also investigated whether these markers could be influenced by comorbidities such as depression and anxiety.

Read the detailed description

Sixty subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of University Hospital of Athens between January to March 2016. 30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives.

Initially, the participants completed the Hamilton Anxiety (HAM-A), Scale Beck Depression Inventory (BDI). All patients had to keep a headache diary during the four-week run-in period. All headache suffers were instructed to collected salivary headache-free baseline samples at the time of study screening when they had been free of headache for at least 48 hours (time point A). All headache suffers collected additional samples during moderate/severe headache (time point B), and at self-defined resolution phase 24 hours of their headache attack (time point C). Healthy control subjects were instructed to collected samples at the time of study screening (time point D). Every week, until four weeks and one month after the end of the study, participants were contacted, in order to ensure the compliance and the appropriate use of the technique. One year later longitudinal data would also be obtain.

Saliva Sample Collection Detailed instructions for the correct collection of saliva samples were given to all participants. Such instructions include avoiding eating a major meal and teeth brushing 60 minutes prior to sample collection. Also consumption of high sugar and caffeine content foods as well as high acidity foods have to be excluded before saliva sample collection. Mouth rinse with water in order to remove any food residue and saliva sample collection at least 10 minutes after mouth rinse was recommended. Unstimulated whole saliva that pooled on the mouth floor were collected from patients and healthy volunteers in high quality polypropylene vials by the passive drool technique. Finally, all samples were stored in a plastic container at 2-4 ° C until analysis. Saliva was collected from the participants, at 8.00 a.m. in the morning in order to rule out any confounding factor caused by circadian rhythm.

Sample Analysis Morning samples were kept in the refrigerator at 4°C and at the end of the day were brought to the laboratory where they were centrifuged 3000 rpm at 4°C and the supernatant was aliquoted in to polypropylene Cryogenic vials. Vials were frozen in -80°C until analyzed. Saliva transferrin levels were measured by competitive immunoassay kits and Interleukin-6, Interleukin-1β and CRP levels were measured by sandwich ELISA kits. Transferrin levels were used as a screening tool for the presence of blood in saliva samples and samples with transferrin values greater than 1 mg/dl were considered as candidates for exclusion in other salivary assays. Cortisol assay has a sensitivity of < 0.007 μg/ml and an inter-assay coefficient of variation of < 11% while these characteristics are 0.07 pg/ml and 8 for Interleukin-6, 0.37 pg/ml and 7 for Interleukin-1β, 10 pg/ml and 11.2 for CRP as well as 0.08 mg/dl and 7.2 for transferrin respectively.

Keywords
Primary headaches, CRP, Interleukin1β, Interleukin6, markers
Medical subject headings
Migraine Disorders, Tension-Type Headache

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03727672
Study groupRoleWhat they receive
Tension type headache patients30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
Migraine patients30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
age matched controls30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. migraine/Tension type Headache and C reactive protein

    establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of C reactive protein

    Measured: 2 years

  2. migraine/Tension type Headache and Interleukin -1β

    establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-1β

    Measured: 2 years

  3. migraine/Tension type Headache and Interleukin-6 levels

    establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-6 levels

    Measured: 2 years

Secondary outcomes (5)
  1. C reactive protein concentrations

    C reactive protein concentrations as assessed using sandwich ELISA kits

    Measured: 2 years

  2. Interleukin-1β concentrations

    Interleukin-1β concentrations as assessed using sandwich ELISA kits

    Measured: 2 years

  3. Interleukin-6 levels concentrations

    Interleukin-6 levels concentrations as assessed using sandwich ELISA kits

    Measured: 2,5 years

  4. Anxiety

    Anxiety as assessed using the Hamilton Anxiety (HAM-A)

    Measured: 2,5 years

  5. Depression

    Depression as assessed using the Beck Depression Inventory (BDI)

    Measured: 2,5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2018
  2. Study start1 Jan 2016
  3. Primary completion30 Dec 2020 (estimated)
  4. Study completion30 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03727672
Sponsor's protocol ID
638/5.11.2015
Acronym
SalHead
Status last verified
Sep 2020
First submitted
23 Oct 2018
Last updated
10 Sep 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: database

Publications

  • Sjogren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun. 2006 May;20(3):270-8. doi: 10.1016/j.bbi.2005.08.001. Epub 2005 Sep 23.

    PubMed 16183246

Questions about this trial

What is this clinical trial studying?

An observational study of Migraine and Tension-Type Headache, run by National and Kapodistrian University of Athens at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

migraine/Tension type Headache and C reactive protein (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03727672, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in